PATENT CLAIM ANALYSIS

Application Number: 16115135
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "513000"]

Abstract:
The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.

Claim (Index 17):
The method of  claim 12 , wherein the ADCY inhibitor is 9-(tetrahydro-2-furanyl)-adenine); 2\u2032,5\u2032-dideoxyadenosine; 9-cyclopentyladenine; 2\u2032,5\u2032-dideoxyadenosine 3\u2032-diphosphate; 2\u2032,5\u2032-dideoxyadenosine 3\u2032-monophosphate; cis-N-(2-phenylcyclopentyl)azacyclotridece-1-en-2-amine); 2-amino-7-(4-chlorophenyl)-7,8-dihydro-5 (6H)-quinazolinone; 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); 2-amino-7-(4-methoxyphenyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-phenyl-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-furanyl)-7,8-dihydro-5(6H)-quinazolinone; 2-amino-7-(2-thienyl)-7,8-dihydro-5(6H)-quinazolinone); MANT-ATP; MANT-ITP; MANT-GTP; MANT-XTP; MANT-CTP; MANT-UTP; 2\u2032-MANT-3\u2032dATP; 3\u2032-MANT-2\u2032dATP; MANT-ATP\u03b3S; MANT-UP\u03b3S; MANT-GTP\u03b3S; MANT-UTP\u03b3S; ANT-ATP; Cl-ANT-ATP; Cl-ANT-ITP; Br-ANT-ITP; Pr-ANT-ATP; Pr ANT-M3; AcNH-ANT-ATP; AcNH-ANT-ITP; MANT-AppNHp; MANT-GppNHp; TNP-ATP; TNP-GTP; TNP-CTP; TNP-UTP, Bis-MANT-ATP; Bis-MANT-ITP, Bis-MANT-CTP; Bis-MANT-IDP, Bis-MANT-IMP; Bis-Cl-ANT-ATP; Bis-Cl-ANT-ITP; Bis-Br-ANT-ATP; Bis-Br-ANT-ITP, Bis-Pr-ANT-ATP; Bis-Pr-ANT-ITP; Bis-AcNH-ANT-ATP; Bis-AcNH-ANT-ITP; NKY80; vidarabine; 2\u2032,5\u2032-dd-3\u2032-ATP; AraAde; PMC6; NB001, BODIPY-FS; 1,9-dd-FS, 6A7DA-FS; Calmidazolium; Tyrphostin A25; 9-Cyclopentyladenine monomethanesulfonate; (E)-2-(1H-Benzo[d]imidazol-2-ylthio)-N\u2032-(5-bromo-2-hydroxybenzylidene)propanehydrazide; SB-268262; LRE1; 2\u2032,5\u2032-Dideoxyadenosine, 2\u2032,5\u2032-Dideoxyadenosine 3\u2032-triphosphate tetrasodium salt; adrenocorticotropic hormone; brain natriuretic peptide (BNP); or pituitary adenylate cyclase-activating polypeptide; or a pharmaceutically acceptable salt of any of the foregoing.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 96.0
- Lexical Diversity: 1.11111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15415112', '14863148', '11421888', '11920473', '13660010']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7457071312270653
- 35 USC 102 Novelty (BERT): 0.5351726149646371
- Combined Prediction Score: 0.7246536796008226
- Mean Citation Score: 244.239444
- Max Citation Score: 339.8744200000001
- Similarity Product: 242.81221903306968

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test